News
The latest company updates, news, and insights
Fierce Biotech names Triveni Bio a “Fierce 15” Biotech Company of 2025
WATERTOWN, MA – September 22, 2025 – Triveni Bio, Inc., a biotechnology company focused on developing innovative antibody treatments for inflammation and immunology (I&I) disorders, today announced that Fierce Biotech has named it as one of 2025’s Fierce 15 biotechnology companies, designating it as one of the most innovative and promising private biotechnology companies in the industry.
Triveni is advancing lead clinical stage asset TRIV-509, a dual-specific monoclonal antibody targeting KLK5/7, into patients with moderate-to-severe atopic dermatitis (AD). Kallikreins 5 and 7 (KLK5/7) are validated targets central to disease pathology that are overexpressed in AD. TRIV-509 shows unique potential to treat all three pillars of AD: barrier dysfunction, inflammation, and itch. Triveni aims to break the efficacy ceiling of current AD treatments, which leave approximately two-thirds of patients with inadequately treated itch and barrier.
“We’re thrilled to see our differentiated approach recognized by Fierce Biotech,” said Vishal Patel, Ph.D., Chief Executive Officer of Triveni Bio. “Underpinning this work is a nimble, relentless team taking calculated risks to advance multiple programs from ideation to the clinic. With TRIV-509, we are making critical progress toward our goal of breaking the existing AD treatment efficacy ceiling through our novel biology.”
“Over the past 23 years, our Fierce 15 special report has spotlighted the private biotechs pushing science into uncharted territory, whose approaches and discoveries represent genuine leaps forward,” said Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare, “This year we’ve selected 15 pre-commercial biotechs that are advancing transformative science in an unrelenting industry landscape. These companies exemplify the innovation and determination driving the next generation of therapies that will hopefully benefit patients worldwide.”
Triveni is advancing a broader pipeline alongside TRIV-509 that includes next-generation bispecific antibody TRIV-573, which combines KLK5/7 with IL-13 inhibition and is expected to be in the clinic in the second quarter of 2026.
About TRIV-509
Triveni’s lead program, TRIV-509 (anti-kallikreins 5 & 7), is a half-life extended monoclonal antibody being positioned for the treatment of moderate-to-severe atopic dermatitis (AD). Through its mechanism, TRIV-509 has demonstrated the ability to directly impact each key pillar of AD – barrier dysfunction, inflammation, and itch. TRIV-509 has demonstrated superior efficacy compared to IL-4R inhibition in multiple preclinical AD models and shown rapid improvement in AD patient explants. TRIV-509 is a clinical stage program being positioned for quarterly subcutaneous dosing.
About TRIV-573
TRIV-573 is a half-life extended second-generation bispecific antibody which combines TRIV-509 with a highly potent anti-interleukin 13 mechanism (IL-13). IL-13 inhibition has been demonstrated in humans to improve outcomes in AD patients. TRIV-573 is currently in IND-enabling studies and is expected to be in the clinic in the first half of 2026.
About Triveni Bio
Triveni Bio is a biotechnology company at the forefront of novel antibody-based therapies for immunological and inflammatory disorders. Using a genetics-informed, precision medicine approach, the company seeks to establish proof-of-concept early in the drug development process by leveraging deep insights into genetic and mechanistic biology. To learn more, visit www.triveni.bio.
Media Contact
Peg Rusconi, Deerfield Group